NASDAQ · RNTX
Healthcare · Medical - Pharmaceuticals
$0.83
Down-$0.05 (-5.63%)
Updated Sep 10, 2026, 9:02 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
RNTX closed at $0.83 after 20 trading sessions, up 2.80% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $0.88 | $0.88 | $0.8221 | $0.8275 | 265.27K |
| Sep 8, 2026 | $0.93 | $0.9598 | $0.85 | $0.8625 | 763.81K |
| Sep 4, 2026 | $0.92 | $0.92 | $0.85 | $0.8891 | 986.05K |
| Sep 3, 2026 | $0.79 | $0.87 | $0.79 | $0.8436 | 568.11K |
| Sep 2, 2026 | $0.76 | $0.791 | $0.7363 | $0.7748 | 489.08K |
| Sep 1, 2026 | $0.749 | $0.765 | $0.7293 | $0.7527 | 344.26K |
| Aug 31, 2026 | $0.77 | $0.7762 | $0.7407 | $0.7499 | 546.08K |
| Aug 28, 2026 | $0.7884 | $0.7884 | $0.7621 | $0.7621 | 259.03K |
| Aug 27, 2026 | $0.7923 | $0.8112 | $0.7825 | $0.7828 | 136.47K |
| Aug 26, 2026 | $0.81 | $0.8241 | $0.78 | $0.80 | 324.71K |
| Aug 25, 2026 | $0.8044 | $0.822 | $0.7707 | $0.80 | 276.75K |
| Aug 24, 2026 | $0.82 | $0.8241 | $0.77 | $0.80 | 463.56K |
| Aug 21, 2026 | $0.80 | $0.855 | $0.7707 | $0.818 | 583.53K |
| Aug 20, 2026 | $0.8563 | $0.8765 | $0.775 | $0.7936 | 2.49M |
| Aug 19, 2026 | $0.80 | $0.8186 | $0.7704 | $0.792 | 352.9K |
| Aug 18, 2026 | $0.8492 | $0.8774 | $0.77 | $0.7701 | 525.3K |
| Aug 17, 2026 | $0.82 | $0.8599 | $0.7754 | $0.8413 | 296.67K |
| Aug 14, 2026 | $0.81 | $0.8171 | $0.7601 | $0.806 | 216.07K |
| Aug 13, 2026 | $0.81 | $0.8297 | $0.78 | $0.7875 | 217.52K |
| Aug 12, 2026 | $0.8227 | $0.8232 | $0.8039 | $0.805 | 79.86K |
The latest Smart Investors Daily articles mentioning RNTX.
RNTX research
Company profile and research snapshot.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 18, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 20, 2026 | Maxim Group | Buy | — |
| Jun 1, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 21, 2026 | Brookline Capital | Hold | — |
| Sep 22, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 20, 2026
Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progressionActively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03
Benzinga · Aug 18, 2026
HC Wainwright & Co. analyst Brandon Folkes reiterates Rein Therapeutics (NASDAQ:RNTX) with a Buy and maintains $8 price target.
Benzinga · Aug 14, 2026
Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.17) by 41.18 percent. This is a 64.29 percent increase over losses of $(0.28) per share
Yahoo · Jul 21, 2026
Global Expansion Complete as Germany Joins Ongoing Study of Inhaled LTI-03 in Idiopathic Pulmonary FibrosisCompany on track to report initial topline data in 2H 2026 AUSTIN, Texas, July 21, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced that its Phase 2 RENEW clinical trial is now open and enro
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RNTX.
